20.500.12556/DiRROS-24535 Case report: effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis a case series Purpose: This study aimed to assess the efficacy of Janus kinase inhibitors (JAK-i) in the treatment of refractory isolated non-infectious uveitis. Case presentation: We examined a case series involving three patients with isolated non-infectious uveitis, who were managed between December 2019 and December 2023 at The Eye Hospital, University Medical Centre Ljubljana. The JAK-i therapy was initiated due to the patients’ unresponsiveness to disease-modifying antirheumatic drugs. Outcomes: In our case series, two patients presented with anterior and intermediate uveitis, one with posterior uveitis. None of the patients had any associated systemic disease. After the initiation of JAK-I therapy, all the patients achieved remission lasting for more than 1 year. No significant side effects were observed in any of the patients throughout a mean follow-up period of 31.6 months (range, 16–55 months). Conclusion: In this report, we present three cases of refractory isolated non-infectious uveitis successfully treated with JAK-i. This is the first report on the use of baricitinib and upadacitinib in this context. Our findings suggest that alternative use of JAK-i, apart from tofacitinib alone, may be an effective treatment option for such patients. JAK inhibitors uveitis biologics true false true Angleški jezik Ni določen Neznano 2025-12-04 13:11:09 2025-12-04 13:11:09 2026-03-12 13:47:46 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 26. 5. 2025; 7 str. [article no.] 1509404 Vol. 16 2025 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 61 1663-9812 10.3389/fphar.2025.1509404 237141507 RAZ_Krhlikar_Nina_2025.pdf RAZ_Krhlikar_Nina_2025.pdf 1 3F0B4A738BFFD5FB12FA2D6F336ECCEC 7f3a581a78b9781a47885ef0a32e0d41bed525caca99763e63c54c316cc9ca4c c3a6a81a-d10a-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36586 https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1509404/full 1 53094d34-d10a-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36585 Univerzitetni klinični center Ljubljana 0 0 0